Hemax Indications/Uses

Treatment of anaemia of chronic renal failure (CRF) patients: Hemax is indicated in adult and pediatric patients on dialysis (end-stage renal failure) as well as in those not requiring dialysis, to enhance or maintain the red cell level (as evidenced by the hematocrit or haemoglobin determinations) and to reduce the need for transfusions. Hemax should not be administered as an emergency transfusion substitute in patients requiring immediate correction of a severe anaemia.
Treatment of anaemia in HIV-infected patients zidovudine-induced anemia: Hemax is indicated for the treatment of anaemia associated with zidovudine therapy of HIV-infected patients to increase or maintain the red blood cell level (as evidenced by hematocrit or haemoglobin values) and to reduce the need for red blood cell transfusions. It is not indicated for the treatment of HIV-infected patients with anaemia of other aetiology (iron or folate deficit, haemolysis, gastrointestinal haemorrhage).
Treatment of anaemia in cancer patients on chemo therapy-induced anemia: Hemax is indicated for the treatment of symptomatic anaemia caused by chemotherapy in patients with metastases of non-myeloid malignancies. Treatment with erythropoietin has shown to reduce the need for red blood cell transfusions in patients on concomitant chemotherapy during a minimal 2-month period. Hemax is not indicated to treat anaemia related to other factors (iron or folate deficit, haemolysis, gastrointestinal haemorrhage) in this group of patients. Hemax is not indicated in patients receiving hormone therapy, biological products or radiotherapy without concomitant bone marrow suppressive chemotherapy.
Hemax is not indicated for patients receiving chemotherapy when the anticipated outcome is cure.
Reduction of allogeneic blood transfusion in anaemic patients who undergo elective surgery: Hemax is indicated in anaemic patients (haemoglobin between 10 and ≤13 g/dl) at high risk for perioperative blood loss from elective, non-cardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. It is indicated for patients at high risk for the need of perioperative transfusions with significant, anticipated blood loss. Hemax is not indicated anaemic patients who are willing to donate autologous blood.
Treatment of anaemia in premature infants: Hemax is indicated for the treatment of anaemia in preterm infants with a body weight between 750 and 1,500 g at birth and a gestational age under 34 weeks.